|Bid||3.45 x 2200|
|Ask||4.47 x 4000|
|Day's Range||3.63 - 3.76|
|52 Week Range||2.05 - 8.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Watertown, Massachusetts-based company said it had a loss of 42 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
Tetraphase Pharmaceuticals (TTPH) posted $98.0 million in operating expenses in fiscal 2017, compared with $63.7 million in fiscal 2016. This $34.3 million rise resulted from increased expenses related to the company’s eravacycline Phase 3 studies. Other primary factors included higher drug manufacturing and nonclinical costs in support of its New Drug Application (or NDA) and precommercialization activities for eravacycline.
Tetraphase Pharmaceuticals (TTPH) generated contract and grant revenues of $9.6 million in fiscal 2017 compared with $5.1 million in fiscal 2016. Until now, the primary source of revenues for the company has been US government contracts.
Tetraphase Pharmaceuticals (TTPH) is developing eravacycline, a fully synthetic flurocycline for use as a first-line empiric monotherapy for treating multidrug-resistant infections. These infections include gram-negative infections such as those found in complicated intra-abdominal infections (or cIAL).
Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS over the last few months. AsRead More...
The Watertown, Massachusetts-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) announced Tuesday that the U.S. Food and Drug Administration accepted a New Drug Application for eravacycline, an antibiotic for complicated intra-abdominal ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) stock ...
Investors in Tetraphase Pharmaceuticals (TTPH) need to pay close attention to the stock based on moves in the options market lately.
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) didn’t have a great start to the week this week. The company just put out data from a phase 3 clinical trial of one of its lead development assets, a drug called intravenous (IV) eravacycline, and the data has failed to hit the mark on a number of endpoints. In response, […] The post Here’s What’s Moving Tetraphase appeared first on Market Exclusive.
Several companies made headlines after hours Tuesday, including Moneygram International Inc (NASDAQ:MGI), Trevena Inc (NASDAQ:TRVN) and Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Moneygram International’s big-money deal did not go through. This isn’t the first deal between a Chinese party and the U.S. that was rejected by the administration of U.S. President Donald Trump.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Tetraphase Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Tetraphase Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTPH-US. Comparing the performance and risk of Tetraphase Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)